Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Authors
Keywords
-
Journal
DIABETES CARE
Volume 45, Issue 11, Pages 2644-2652
Publisher
American Diabetes Association
Online
2022-09-22
DOI
10.2337/dc22-0866
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives
- (2022) Frederik Flindt Kreiner et al. Expert Review of Clinical Immunology
- A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
- (2021) Taha Sen et al. Cell Metabolism
- Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
- (2021) Paul M Ridker et al. CIRCULATION RESEARCH
- IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
- (2021) Paul M Ridker et al. LANCET
- Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
- (2021) Taha Sen et al. DIABETOLOGIA
- Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome
- (2021) Gorav Batra et al. JAMA Cardiology
- Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy
- (2021) Beatriz Sanchez-Alamo et al. CLINICAL NEPHROLOGY
- Inflammation in Metabolic Cardiomyopathy
- (2021) Florian A. Wenzl et al. Frontiers in Cardiovascular Medicine
- Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6
- (2020) Daniel J. Tyrrell et al. Nature Reviews Cardiology
- Anticytokine Agents
- (2019) Paul M Ridker CIRCULATION RESEARCH
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
- (2019) Hiddo J. L. Heerspink et al. DIABETOLOGIA
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease
- (2018) Radica Z. Alicic et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
- (2018) Paul M Ridker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
- (2018) Brendan M. Everett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
- (2017) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial
- (2017) Claes Held et al. Journal of the American Heart Association
- Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update
- (2017) Hua Su et al. Frontiers in Immunology
- From C-Reactive Protein to Interleukin-6 to Interleukin-1
- (2016) Paul M Ridker CIRCULATION RESEARCH
- Inflammation and Progression of CKD: The CRIC Study
- (2016) R. L. Amdur et al. Clinical Journal of the American Society of Nephrology
- Inflammatory processes in cardiovascular disease: a route to targeted therapies
- (2016) Neil Ruparelia et al. Nature Reviews Cardiology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study
- (2013) Anne Ofstad et al. Cardiovascular Diabetology
- Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis
- (2013) S. Kaptoge et al. EUROPEAN HEART JOURNAL
- Inflammation and Coagulation Markers and Kidney Function Decline: The Multi-Ethnic Study of Atherosclerosis (MESA)
- (2012) Jade S. Hiramoto et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More